Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind

FierceBiotechAscendis axes IL-2 program in retreat from oncology expansion

PharmaVoiceNovo hikes guidance on Wegovy pill’s fast sales start

Endpoints NewsAmgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany

FierceBiotechEntrada's stock craters as DMD data underperform expectations, handing advantage to Novartis

FierceBiotechRoche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics

Promega BlogWhat Counts as Evidence

FierceBiotechFrom drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’

Lonza NewsBMS Licenses SYNtecan Linker-Payload Platform from Lonza - Contract Pharma

IlluminaAi In Genomics Market Is Going to Boom | Illumina, IBM, Google - openPR.com

Endpoints NewsAtara, Pierre Fabre's cell therapy to get another shot at FDA approval

FierceBiotechInsulet boosts guidance in Q1 update as it grapples with recall saga

PharmaVoiceLilly, Gilead lead pharma’s M&A boom